AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Creative Financial Designs Inc. ADV boosted its holdings in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 0.5% during the 4th quarter, Holdings Channel.com reports.The fund owned ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

Alphabet’s new Gemini 2.5 Pro model has surpassed rival AI systems, earning top scores on major benchmarks and excelling in coding and reasoning tasks. Its advantage comes from a trifecta of ...

Theoretically, the long-term market for quantum computing for Google includes quantum chemistry for batteries, drug design ... the 2022 Fed tightening cycle, Alphabet's P/E dropped to around ...